Synonyms: Savella®
milnacipran is an approved drug (FDA (2009))
Compound class:
Synthetic organic
Comment: Milnacipran is approved as a racemic mixture of enantiomers. We show the non-isomeric structure to represent the mixture.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖![]() View more information in the IUPHAR Pharmacology Education Project: milnacipran |
|
References |
1. Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y. (2010)
Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 62 (9): 2745-56. [PMID:20496365] |
2. Moret C, Briley M. (2006)
Antidepressants in the treatment of fibromyalgia. Neuropsychiatr Dis Treat, 2 (4): 537-48. [PMID:19412502] |
3. Van Orden LJ, Van Dyke PM, Saito DR, Church TJ, Chang R, Smith JA, Martin WJ, Jaw-Tsai S, Stangeland EL. (2013)
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships. Bioorg Med Chem Lett, 23 (5): 1456-61. [PMID:23347683] |